Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00700687

Acronym

PA32540-109

Enrollment

Registered

2008-06-19

Start date

2008-06-30

Completion date

2008-07-31

Last updated

2009-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

cardiovascular prophylactic therapy

Brief summary

We will evaluate the effect on the gastroduodenal mucosa from oral dosing of three different treatments

Interventions

DRUGPA32540

aspirin/omeprazole

DRUGPA32540 and celecoxib

aspirin/omeprazole and celecoxib

DRUGaspirin and [NSAID]

aspirin and \[NSAID\]

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Healthy male or non-pregnant female subjects greater than or equal to 50 years as well as other standard inclusion criteria for a study of this nature

Exclusion criteria

* Standard

Design outcomes

Primary

Measure	Time frame
Lanza scores	entire course of study

Secondary

Measure	Time frame
safety of three treatments	entrie course of study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026